TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Seven studies by Mayo Clinic researchers examine how senescent cells differ across tissues, contribute to inflammation and may be targeted or monitored. Experiments in older mice showed promising effects, but the findings do not establish safe or effective treatments for people.
Mayo Clinic researchers have published seven studies examining how senescent cells vary across tissues, contribute to chronic inflammation and might be targeted, adding new findings to research into age-related disease. The work includes experiments in older mice, but does not show that the proposed approaches are safe or effective in people.
The studies were conducted by scientists at Mayo Clinic’s Robert and Arlene Kogod Center on Aging and published in Nature journals, according to the source report. Senescent cells stop dividing but remain biologically active. They can release inflammatory substances, a collection of signals often described as the senescence-associated secretory phenotype, or SASP. The new work investigates not just whether these cells are linked to aging, but how to identify different populations and understand their effects.
One study addresses a longstanding identification problem: senescent cells do not share one uniform profile. Their characteristics can vary with tissue and with the biological process that caused senescence. Researchers developed SenMayo, a gene set intended to help identify these cells more consistently across tissues and experimental systems. They tested it using bone biopsies from older adults and reported that its gene signature became less prominent after senescent cells were removed in preclinical experiments.
Other studies examined links between malfunctioning mitochondria and inflammatory activity. The researchers reported that mitochondrial DNA and RNA can activate immune responses, while changes in mitochondrial metabolism may affect inflammatory gene activity through epigenetic mechanisms. Their findings point to a possible strategy of reducing harmful signals without necessarily eliminating the senescent cells.
The team also tested approaches including senolytic medications, a natural compound found in tomatoes and genetic methods aimed at selected cell populations. In older mice, the interventions were associated, depending on the approach, with lower inflammatory measures and improvements in outcomes such as physical frailty, brain inflammation and performance on cognitive tasks. A separate study identified IL-23R as a potential aging-related biomarker in blood and tissue. These are research findings, not validated medical tests or treatments.
Toward More Precise Cell Targeting
The work matters because it suggests that research on aging may need to distinguish among different senescent cell populations, rather than treating them as one target. If those differences can be reliably mapped, future studies could test whether particular cells or inflammatory pathways are more relevant to specific age-related conditions.
The mitochondrial findings also broaden the possible intervention strategy. Destroying senescent cells is one proposed route, but reducing the inflammatory activity they produce could offer another. The mouse results provide experimental leads; they do not establish that either approach will prevent disease, extend human life or improve health in patients. Clinical benefit, safety and suitable dosing remain unproven.
A reliable biomarker could help researchers track biological changes or evaluate experimental treatments, but IL-23R is described as a potential marker, not an established measure of an individual’s age or health. Its performance and meaning in people require further study.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Bonus Bands
Therabody SleepMask Blackout Eye Mask with Vibration
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
As an affiliate, we earn on qualifying purchases.
SenNet Maps Cells Across Tissues
The studies contribute to the Cellular Senescence Network Consortium, known as SenNet, a U.S. research effort funded by the National Institutes of Health Common Fund. Its goal is to document where senescent cells occur in different tissues and how they change over a person’s lifetime. The Mayo report presents the seven studies as part of that broader effort to build a clearer picture of these cells.
SenMayo was developed to address variation in how senescence is identified. The source report says the gene set has become a widely used research resource, while the study tested it in human bone samples and preclinical settings. The consortium’s mapping goal reflects a related challenge: a marker or pattern seen in one tissue may not reliably describe senescent cells elsewhere.
Mayo scientist Marissa Schafer, whose laboratory directed several investigations, said the work is intended to support more precise identification and targeting of cells linked to age-related dysfunction. The source report identifies Mayo endocrinologist Sundeep Khosla as senior author of the SenMayo study and João Passos as senior author of three papers on senescent-cell diversity and mitochondrial mechanisms.
“This body of work is moving the aging field forward to precisely identify, understand and target the specific senescent cells that contribute to age-related dysfunction, which is the necessary groundwork to develop new therapies that support healthy aging.”
— Marissa Schafer, Ph.D., Mayo Clinic scientist
Human Benefits Remain Unproven
The source report does not establish that the interventions tested in mice will work in people. It gives no human trial results demonstrating that senolytic drugs, the tomato-derived compound or genetic targeting approaches are safe or effective for treating age-related conditions. The specific compounds, doses, study sizes and duration of the animal experiments are also not detailed in the supplied report.
It is also unclear how SenMayo and IL-23R would perform across a wider range of people, tissues and diseases, or whether either could guide treatment decisions. The report describes IL-23R as a potential biomarker; it does not say that it is ready for routine testing. More research is needed to determine which cell types and pathways matter in specific conditions and whether changing them produces lasting health benefits.
Further Testing Before Clinical Use
The next steps are further laboratory and preclinical work to validate the cell-identification methods, clarify the mechanisms behind inflammation and test whether the approaches can be used safely. Researchers would also need to establish whether the findings translate to human tissues and, eventually, whether carefully designed clinical studies show meaningful benefit for patients.
SenNet researchers are working toward broader maps of senescent cells across tissues and over the lifespan. Such maps may help define which populations should be studied and how future interventions could be measured. For now, the Mayo studies supply research tools and experimental leads; they do not support a claim that an anti-aging treatment is available.
Key Questions
What are senescent cells?
They are cells that have stopped dividing but remain active. Some release inflammatory signals that researchers associate with age-related dysfunction.
Did the Mayo studies test treatments in people?
The source report describes promising experiments in older mice, along with tests of SenMayo using bone biopsies from older adults. It does not report human treatment trials establishing safety or effectiveness.
What is SenMayo?
SenMayo is a gene set developed to help researchers identify senescent cells more consistently across tissues and experimental systems. It is a research tool, not a medical treatment.
What is IL-23R’s role in the findings?
The researchers identified IL-23R as a potential biomarker associated with senescence in blood and tissue. Its use as a test for aging or to monitor treatment has not been established.
Could these findings lead to an anti-aging treatment?
The studies may inform future research into age-related diseases, but they do not show that an anti-aging treatment is available or proven. Human safety and benefit remain to be tested.
Source: sciencedaily.com
